Thrombosis in the Young: Epidemiology and Risk Factors. A Focus on Venous Thrombosis

Rosendaal, F. R.

doi:10.1055/s-0038-1657492

Cited by 290 publications

(197 citation statements)

References 41 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…The results agree with the literature, which reports the increased risk of thrombosis and/or thrombus formation with age, e.g., Anderson Jr et al (1991), Oger (2000), Rosendaal (1997), Lee et al (2011) andOrra (2002). When using the method of Wells et al (1995Wells et al ( , 1997, the two patients with thrombosis were rated at least moderate, which was consistent with the occurrence of thrombosis.…”

Section: Discussionsupporting

confidence: 92%

A novel method for predicting the risk of thrombosis and thromboembolism

Leite

Marques

2014

Rev. Bras. Eng. Bioméd.

View full text Add to dashboard Cite

Introduction: Thrombosis is a complex disease that is often silent and is characterized by thrombus formation within the blood vessel. It can lead to a venous obstruction in the body, severe sequelae and even death. Thrombus formation occurs when there is reduced blood flow and/or the release of procoagulant substances caused by external factors. In Brazil, the data on this pathology are still underestimated, and its incidence is approximately 0.8 cases/1000 inhabitants per year according to the literature. The aim of this study was to develop and validate a predictive method for the risk of thrombosis or thromboembolism according to various risk factors. Methods: This is an observational and retrospective study based on a convenience sample of records. It was approved by the Institutional Review Board (IRB) of the University Mogi das Cruzes and the Heart Hospital of the São Paulo. The sample was classified according to the risk, and the assessment of concordance was performed by determining the Kappa coefficient and accuracy. Results: Of the observed patients, 23 (46%) were women, and 86% were over 45 years old. The mean age of the patients was 60.8 years. Forty-eight percent of the patients underwent surgery for more than 30 minutes. In this study, the method categorized 29 (58%) patients as moderate risk, 10 as low risk and 11 as high risk. Two cases of thrombotic disease were sufficient for validation. Conclusion: The use of this software as a predictive method was feasible, providing fast filling, immediate scoring, flexibility and an upgrade over previous systems. The software will not substitute for diagnosis, which is a medical competence, but it may help as a warning of risk.

show abstract

Section: Discussionsupporting

confidence: 92%

A novel method for predicting the risk of thrombosis and thromboembolism

Leite

Marques

2014

Rev. Bras. Eng. Bioméd.

View full text Add to dashboard Cite

show abstract

“…In our studies, the overall annual acute thrombosis rate was within the same range as these studies, 1.33 per 100 patient-years in the APLASA study and 2.20 per 100 patient-years in the observational study. The thrombosis risk in the general population rises with the increasing number of thrombosis risk factors and age (19). Thus, it is not clear if aPL is the only risk factor needed for every individual to develop thrombosis.…”

Section: Discussionmentioning

confidence: 99%

Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double‐blind, placebo‐controlled trial in asymptomatic antiphospholipid antibody–positive individuals

Erkan¹,

Harrison²,

Levy³

et al. 2007

Arthritis & Rheumatism

365

206

View full text Add to dashboard Cite

Objective. To determine the efficacy of a daily dose of 81 mg aspirin in primary thrombosis prevention in asymptomatic, persistently antiphospholipid antibody (aPL)-positive individuals (those with positive aPL but no vascular and/or pregnancy events).Methods. The Antiphospholipid Antibody Acetylsalicylic Acid (APLASA) study was a multicenter, randomized, double-blind, placebo-controlled clinical trial in which asymptomatic, persistently aPL-positive individuals were randomized to receive a daily dose of 81 mg of aspirin or placebo. In a separate observational and parallel study, asymptomatic, persistently aPL-positive individuals who were taking aspirin or declined randomization were followed up prospectively.Results. In the APLASA study, 98 individuals were randomized to receive aspirin or placebo (mean ؎ SD followup period 2.30 ؎ 0.95 years), of whom 48 received aspirin and 50 received placebo. In the observational study, 74 nonrandomized individuals were followed up prospectively (mean ؎ SD followup period 2.46 ؎ 0.76 years); 61 received aspirin and 13 did not. In the APLASA study, the acute thrombosis incidence rates were 2.75 per 100 patient-years for aspirin-treated subjects and 0 per 100 patient-years for the placebo-treated subjects (hazard ratio 1.04, 95% confidence interval 0.69-1.56) (P ‫؍‬ 0.83). Similarly, in the observational study, the acute thrombosis incidence rates were 2.70 per 100 patient-years for aspirin-treated subjects and 0 per 100 patient-years for those not treated with aspirin.

show abstract

“…In children, three or four risk factors are often required to precipitate thrombosis. 47 It seems likely that several risk factors, both genetic and acquired, need to be present for thrombosis to occur. In investigating a new patient with a retinal vein occlusion one should test for hypertension, glaucoma and diabetes mellitus.…”

Section: Discussionmentioning

confidence: 99%